Clover Health to Participate in Upcoming J.P. Morgan 2026 Healthcare Conference
Rhea-AI Summary
Clover Health (Nasdaq: CLOV) said its CEO Andrew Toy will present at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026 at 11:15 a.m. ET.
A live webcast and a replay of the presentation and Q&A will be available on Clover Health's investor relations website at https://investors.cloverhealth.com/.
Positive
- None.
Negative
- None.
News Market Reaction – CLOV
In the Dec 17 session, CLOV declined 1.52%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 17 | Conference participation | Neutral | +0.0% | CFO scheduled to present at 2025 Citi Global Healthcare Conference. |
| Nov 04 | Earnings update | Positive | -4.3% | Q3 2025 results with revenue growth, raised 2025 guidance, updated profitability metrics. |
| Oct 31 | Board change | Neutral | +4.3% | Chelsea Clinton stepped down from Board after eight years of service. |
| Oct 30 | Technology whitepaper | Positive | +1.7% | Whitepaper showing CA technology linked to earlier diagnosis and fewer hospitalizations. |
| Oct 22 | Conference participation | Neutral | -4.3% | CFO to present at 2025 UBS Global Healthcare Conference with webcast access. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent conference participation headlines have generally produced small to modest price moves, while the Q3 2025 earnings update saw a negative reaction despite revenue growth and raised guidance.
This announcement adds to a series of investor-facing communications from Clover Health in late 2025. In October–November 2025, the company reported Q3 2025 results with revenue growth and updated guidance, published a whitepaper on its Counterpart Assistant technology, and disclosed a board change as Chelsea Clinton stepped down on October 31, 2025. It also highlighted participation in multiple healthcare conferences. Today’s J.P. Morgan 2026 conference participation continues that pattern of maintaining visibility with investors and the healthcare community through regular conference presentations and investor-relations outreach.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WILMINGTON, Del., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Executive Officer, Andrew Toy, will present at the J.P. Morgan 2026 Healthcare Conference on Thursday, January 15, 2026, at 11:15 a.m. Eastern Time.
A live webcast and replay of the presentation and Q&A session will be accessible on Clover Health's investor relations website at https://investors.cloverhealth.com/.
About Clover Health:
Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, and in Underserved Populations as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.
Investor Relations:
Ryan Schmidt
investors@cloverhealth.com
Press Inquiries:
press@cloverhealth.com
